Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance

Mesenchymal stem cells (MSCs) have attracted attention as a potential therapy for Acute Respiratory Distress Syndrome (ARDS). At the same time, the use of extracorporeal membrane oxygenation (ECMO) has increased among patients with severe ARDS. To date, early clinical trials of MSCs in ARDS have excluded patients supported by ECMO. Here we provide evidence from an ex-vivo model of ECMO to suggest that the intravascular administration of MSCs during ECMO may adversely impact the function of a membrane oxygenator. The addition of clinical grade MSCs resulted in a reduction of flow through the circuit in comparison to controls (0.6 ±0.35 L min-1vs 4.12 ± 0.03 L min-1, at 240 minutes) and an increase in the transoygenator pressure gradient (101±9 mmHg vs 21±4 mmHg, at 240 minutes). Subsequent immunohistochemistry analysis demonstrated quantities of MSCs highly adherent to membrane oxygenator fibres. This study highlights the potential harm associated with MSC therapy during ECMO and suggests further areas of research required to advance the translation of cell therapy in this population.

[1]  R. Flower,et al.  Platelet concentrates modulate myeloid dendritic cell immune responses , 2018, Platelets.

[2]  C. Bermudez,et al.  The Use of GMP-Produced Bone Marrow Derived Stem Cells in Combination with Extra Corporeal Membrane Oxygenation in ARDS -An Animal Model. , 2017, ASAIO journal.

[3]  C. Bermudez,et al.  The Use of GMP-Produced Bone Marrow-Derived Stem Cells in Combination with Extracorporeal Membrane Oxygenation in ARDS: An Animal Model. , 2017, ASAIO journal.

[4]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[5]  T. Luedde,et al.  Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome , 2015, Respiration.

[6]  R. Sandberg,et al.  In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome , 2015, Stem cells translational medicine.

[7]  M. Strueber Artificial lungs: are we there yet? , 2015, Thoracic surgery clinics.

[8]  B. Thompson,et al.  Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. , 2015, The Lancet. Respiratory medicine.

[9]  Q. Shu,et al.  Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study , 2014, Respiratory Research.

[10]  David Stewart,et al.  Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. , 2012, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[11]  J Feldschuh,et al.  Prediction of the Normal Blood Volume: Relation of Blood Volume to Body Habitus , 1977, Circulation.